An editorial is presented which argues Prostate-specific membrane antigen is a type II transmembrane protein highly expressed in almost all stages of prostate cancer (>90%). It also discusses that PSMA-targeted radionuclide imaging is now signifcantly impacting clinical decisionmaking in about 54 percent of patients.